id: melatonin_supplementation_to_sleep_quality_psqi
name: Melatonin Supplementation (10mg) â†’ Sleep Quality (PSQI Score)
from_node:
  node_id: melatonin_supplementation
  node_name: Melatonin Supplementation (10mg)
to_node:
  node_id: sleep_quality_psqi
  node_name: Sleep Quality (PSQI Score)
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Melatonin administration exerts chronobiotic effects, regulating circadian
  rhythm disruption in COMISA patients'
- 'Step 2: Antioxidant properties of melatonin reduce oxidative stress associated
  with sleep fragmentation'
- 'Step 3: Improved sleep architecture reduces nighttime awakenings and decreases
  sleep latency'
- 'Step 4: Overall sleep quality improves as measured by reduction in PSQI scores'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Tahereh Madani Motlaq et al. 2024. "Effect of melatonin on insomnia
    and daytime sleepiness, in patients with obstructive sleep apnea and insomnia
    (COMISA): A randomized double-blinded placebo-controlled trial." *Journal of Pharmaceutical
    Health Care and Sciences*. https://doi.org/10.1186/s40780-024-00347-9'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:07.021883'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: pap_therapy_use
  direction: strengthens
  strength: moderate
  description: Concurrent PAP therapy use for over one month required for study inclusion,
    suggesting melatonin effects may be enhanced in context of existing OSA treatment
